the biomedical research center focused on applying micro- and
nanotechnology innovations to health care, today announced it has raised
€10 million to support research in diagnosis and treatment of
neurodegenerative diseases, cancer and motor disabilities.
J. Safra Foundation launched the campaign in October 2015, pledging
to match up to €5 million in donations.
“I never doubted that this matching fundraising campaign would be a
success,” said Ms. Lily Safra, president of the foundation. “Prof. Alim
Louis Benabid and Clinatec’s teams are working on breakthrough projects
and carrying so much hope! Created five years ago, Clinatec already has
earned its place among the best medical innovative research centers.”
“The great support we have received from the Edmond J. Safra Foundation
and Lily Safra increases our engagement to go faster and further," said
Prof. Benabid, Clinatec’s CEO.
At Clinatec, 2016 was marked by a consolidation phase that will allow
important clinical developments in 2017:
The Brain-Computer Interface (BCI) project is intended to give
mobility to people affected with quadriplegia. An implant captures
electrical signals from the brain, while an embedded computer decodes
and transcribes the information to an exoskeleton. The first patient
received an implant, analysis of the treatment is underway. A second
patient is expected to receive an implant in 2017 to further
demonstrate the feasibility of a BCI and exoskeleton providing freedom
The Near InfraRed (NIR) project is intended to evaluate the
neuroprotective effect of Near Infra Red light using an intracranial
medical device delivering therapeutic light. When applied to the
precise spot in the brain where PD and other diseases cause
irreversible damage, near-infrared illumination can slow down the
disease progression. The first experimental work were developed at
Clinatec and preclinical results were published in a prestigious
scientific review (Annals of neurology). A clinical trial to confirm
these positive results will be launched in 2017, a first step towards
the cure for Parkinson's disease.
The Epicool project, recently launched by Clinatec, aims to
develop a cooling system implanted in the brain to block seizures, as
applying cold is known to reversibly block neuron activity.
Experimental work and technological development will start in 2017. A
clinical trial is planned in 2020-22.
Clinatec is a partner in a clinical trial, Equoloc project, for
patients affected by obsessive-compulsive (OCD) drug-resistant
disorders, and who are treated with deep brain stimulation. Access to
Clinatec and using its unique imaging tools (including MEG) will
enable the team to study potential brain dysfunctions that may affect
some OCD patients. A European trial has already started, bringing
together psychiatrists and neurosurgeons in Grenoble.
View source version on businesswire.com:
Last updated on: 22/11/2016